Get the Daily Brief
Latest Biotech News
HIV remission signal with CCR5Δ32 donor transplant – report highlights durable clinical outcome
Researchers reported long-term remission of HIV-1 in a patient who received an allogeneic hematopoietic stem cell transplant from a sibling donor carrying the CCR5Δ32/Δ32 mutation. The result,...
Gene-editing immune cell “protein factory” platform advances in Science – CRISPR HSPC reprogramming
Rockefeller University scientists presented a CRISPR-based strategy that reprograms hematopoietic stem and progenitor cells (HSPCs) to produce engineered B-lymphocyte protein “factories.” In mice,...
Biotech capital markets: Revolution Medicines raises $1.5B after Phase 3 daraxonrasib win
Revolution Medicines priced a $1.5 billion follow-on offering and accompanying convertible notes only days after reporting Phase 3 top-line results for daraxonrasib in metastatic pancreatic ductal...
Clinical oncology: daraxonrasib Phase 3 results extend survival in metastatic pancreatic cancer
Revolution Medicines reported positive Phase 3 results for its orally administered RAS-targeting inhibitor daraxonrasib in metastatic pancreatic ductal adenocarcinoma, with outcomes reportedly...
FDA review pipeline: priority review granted for Merck–Daiichi B7-H3 ADC in extensive-stage small-cell lung cancer
The FDA accepted and granted priority review to Daiichi Sankyo and Merck for ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate being evaluated for advanced extensive-stage small-cell...
Diagnostics regulation and market access: Grifols malaria risk donor screening assay approved by FDA
Grifols said the FDA approved its automated Procleix Plasmodium Assay for screening blood donors for malaria risk. The assay is designed for use with the Procleix Panther system and detects...
Med-tech transactions: CareDx to divest lab products business to EuroBio for $170M
CareDx announced a definitive agreement to sell its lab products business to EuroBio Scientific for $170 million in cash. Under the deal, CareDx will provide transition services for at least six...
Structural biology infrastructure: NIH renews Illinois Tech-led BioCAT funding at Argonne APS
Illinois Tech-led BioCAT at Argonne National Laboratory’s Advanced Photon Source secured a $2.6 million renewal award from NIH’s National Institute of General Medical Sciences (NIGMS). The funding...
GLP-1 obesity-to-diabetes expansion with cardiovascular and liver safety data
Eli Lilly’s oral GLP-1 obesity drug Foundayo (orforglipron) cleared a key heart-safety hurdle in people with diabetes, meeting non-inferiority versus insulin glargine in a cardiovascular outcomes...
FDA priority review for B7-H3 ADC in extensive-stage small-cell lung cancer
The FDA granted priority review to Daiichi Sankyo and Merck’s ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, for advanced extensive-stage small-cell lung cancer. The accelerated...
Groundbreaking Phase 3 setback recovery effort for Elevidys in Europe
Roche will start a new global Phase 3 trial for Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys after Europe delivered a negative opinion. The study plans to randomize...
Major next-generation diagnostics deal: Foundation Medicine to acquire Saga Diagnostics’ Pathlight MRD platform
Roche subsidiary Foundation Medicine agreed to buy Saga Diagnostics to expand its molecular residual disease (MRD) portfolio, paying up to $595 million. The acquisition brings Saga’s Pathlight...
RNA epigenetics momentum: Storm raises Series C and treats first patient in sarcoma Phase 2
Storm Therapeutics secured a $56 million Series C to advance STC-15, its RNA enzyme inhibitor targeting myo- and liposarcomas, and reported that the first patient has been treated in a new Phase 2...
HIV remission case strengthens CCR5Δ32 HSCT signal
Researchers reported long-term remission of HIV-1 in a patient who received an allogeneic hematopoietic stem cell transplant from a sibling donor carrying the CCR5Δ32/Δ32 mutation. Published in...
Cell therapy trial readout risk/reward: demethylation-primed dual CD19/CD20 CAR T in lymphoma
Investigators reported early promise from a Phase 1/2a trial of demethylation-primed tandem CD19/CD20 CAR T cells in relapsed or refractory B-cell lymphomas. The approach combines epigenetic...
Startup funding to move protein diagnostics forward via single-molecule amplification tech
Finnish protein sensing startup Proteins.1 raised €4.7 million in pre-seed funding to develop enzyme-free, single-molecule protein amplification for diagnostics. The round was led by Lifeline...
Med-tech/diagnostics revenue volatility: QuidelOrtho’s Q1 dragged by respiratory season softness and China slowness
QuidelOrtho reported preliminary Q1 2026 revenue of $615 million to $620 million, down about 11% at the midpoint versus Q1 2025, citing a lighter respiratory season and slower distributor sales in...
Cancer diagnostics workflow automation: Invivoscribe launches PrepQuant to standardize pre-analytical steps
Invivoscribe introduced PrepQuant, an integrated sample preparation platform designed to standardize nucleic-acid extraction, concentration, and quantification in a single automated instrument....
Obesity GLP-1 competition shifts to liver and safety surveillance
Eli Lilly said its oral obesity drug Foundayo met the main goal of a cardiovascular outcomes study in people with diabetes, showing no greater risk of heart attacks and other cardiovascular events...
Roche reopens Elevidys path toward European approval
Roche announced a new global Phase 3 trial for Duchenne muscular dystrophy gene therapy Elevidys as it tries again for European approval after prior negative European Medicines Agency feedback....